Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 67th Annual Health Research Conference organized by the Caribbean Public Health Agency (CARPHA), taking place from April 27-29, 2023, in the Bahamas. This conference is the largest and longest-running health research event in the Caribbean and Latin America, aimed at promoting collaboration among health scientists and policymakers.
Co-Diagnostics will showcase its infectious disease products, including the upcoming Co-Dx PCR Home™ testing platform, which is currently under FDA review and not yet available for sale. The company has actively participated in CARPHA conferences since 2016 and is well-regarded for its innovative diagnostics technologies.
Co-Diagnostics, Inc. (NASDAQ: CODX) announced its participation in the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The ECCMID is a key event in infectious diseases, attracting over 14,000 attendees and offering a hybrid format for greater accessibility. Co-Dx aims to connect with international customers for its real-time PCR products, including the upcoming Co-Dx PCR Home™ platform, which is currently under FDA review and not yet for sale. Visitors can find the company at Booth B4-04 to learn more about its innovative diagnostics technologies, which focus on nucleic acid detection and analysis.